Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 26;42(23):1913–1925. doi: 10.1038/s41388-023-02670-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — A Overview of representative neoantigens detected in all NSCLC and melanoma samples from ICB cohorts. B The NEO2IS is significantly higher in responders compared with nonresponders (p value <0.05) and shows stronger association with treatment response than TMB in both lung cancers and melanomas. C Kaplan–Meier curves of RFS and OS in patients with high and low NEO2IS or TMB in lung cancer (left panel) and melanoma (right panel) ICB cohorts (quantiles or medians of cohort NEO2IS and TMB used as cut-off points). D Comparison of NLS between responding patients and nonresponding patients in Abbott melanoma cohort. E ROC curves for NEO2IS and TMB in 2 lung cancer cohorts and the combined NSCLC samples. F ROC curves for NEO2IS and TMB in 3 melanoma cohorts and their combined samples.